CEA Trial
The Phase 2 CEA Trial has completed enrollment of 50 patients with significant carotid artery stenosis (narrowing) who have elected to undergo a carotid endarterectomy (CEA).
A CEA is a surgical procedure to remove plaque in the lining of the carotid artery to allow normal blood flow to the brain. Patients in the study are treated once daily with 100mg of oral VIA-2291 or placebo for three months prior to surgery. Investigators will evaluate atherosclerotic plaque tissue from the surgical procedures for evidence of VIA-2291’s effect on inflammation. The study also includes measures of leukotrienes and serum biomarkers of inflammation that are indicative of increased risk of MACE. The CEA study is designed to evaluate the efficacy of VIA-2291 in the vessel wall, and has the unique advantage of providing access to atherosclerotic tissue for direct evaluation of VIA-2291’s effect on inflammation, through a panel of assays and histological examinations.